Wanbury Limited WANBURY

Latest filings

• Approval73 12 Nov, 11:21 · NSE
  A press release dated November 12, 2026, titled "Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HCl EP grade.".
• Results73 6 Nov, 13:27 · NSE
  A press release dated November 06, 2026, titled "Press release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026".
• Board meeting48 4 Nov, 21:08 · BSE
  Outcome of the Board Meeting held on November 04, 2026
• Results73 4 Nov, 20:55 · NSE
  , the financial results for the period ended September 30, 2026.
• Routine15 30 Oct, 12:56 · NSE
  A press release dated October 30, 2026, titled "Wanbury Limited Receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials".
• Board meeting40 28 Oct, 15:23 · BSE
  Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the un-audited Financial Results (Standalone ....
• General38 19 Oct, 14:41 · BSE
  Wanbury Limited Awards for Tanuku and Patalganga Facilities
• General25 16 Oct, 13:12 · BSE
  Wanbury Limited - Regulatory Progress in API Business, New Business Opportunities and Operational Achievements
• General50 12 Oct, 14:57 · BSE
  Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysolftTM baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.
• General65 12 Oct, 13:28 · BSE
  Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoftTM baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.

Shown 15 minutes after publication. Real time with Pro.